AstraZeneca PLC (LON:AZN) Insider Michel Demare Buys 2,000 Shares of Stock

AstraZeneca PLC (LON:AZN) insider Michel Demare purchased 2,000 shares of AstraZeneca stock in a transaction dated Friday, September 13th. The stock was bought at an average cost of GBX 118 ($1.56) per share, with a total value of £2,360 ($3,117.57).

AstraZeneca Price Performance

Shares of LON:AZN opened at £120.16 ($158.73) on Tuesday. AstraZeneca PLC has a 52 week low of GBX 9,461 ($124.98) and a 52 week high of £133.88 ($176.86). The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 84.97. The company has a market cap of £186.25 billion, a P/E ratio of 3,851.28, a PEG ratio of 0.93 and a beta of 0.17. The company has a 50-day moving average price of £125.81 and a 200 day moving average price of £119.05.

AstraZeneca Cuts Dividend

The company also recently announced a dividend, which was paid on Monday, September 9th. Shareholders of record on Thursday, August 8th were paid a GBX 77.60 ($1.03) dividend. The ex-dividend date of this dividend was Thursday, August 8th. This represents a yield of 0.64%. AstraZeneca’s payout ratio is currently 7,500.00%.

Analysts Set New Price Targets

AZN has been the topic of several recent analyst reports. Jefferies Financial Group upped their target price on AstraZeneca from GBX 71 ($0.94) to GBX 74 ($0.98) and gave the company a “hold” rating in a research report on Tuesday, July 2nd. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a £110 ($145.31) target price on shares of AstraZeneca in a research report on Tuesday, September 3rd. Berenberg Bank reaffirmed a “buy” rating and set a £150 ($198.15) target price on shares of AstraZeneca in a research report on Monday, September 2nd. Citigroup reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Tuesday, May 28th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of AstraZeneca in a research report on Monday. One analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of £105.53 ($139.41).

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.